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iate p value for the coefficient of LDL on treatment (p  0.26).
This model suggests that age is more predictive of cancer
incidence than LDL on treatment. Based on this analysis, we
should reconsider the assertion that statin-induced lowering of
LDL is associated with increased cancer incidence.
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Risk Associated
With Statin Treatment
Several prospective, randomized, placebo-controlled trials have
established the fundamental preventive role of statins in the
treatment of atherosclerotic disease, including coronary artery
disease, stroke, and peripheral artery disease. However, in high-
risk cohorts of elderly, hypertensive patients and patients with
heart failure, low cholesterol portends a poor prognosis (1,2). This
controversial association has been ascribed to the role of cholesterol
as a marker of incipient risk, which disappears after accounting for
the early deaths (3). In their retrospective meta-analysis of statin
users in large randomized, controlled trials, Alsheikh-Ali et al. (4)
observed an association between statin-induced lowering of low-
density lipoprotein and increased risk of cancer, and they con-
cluded that this may offset some of the benefits of statins. Their
conclusion of a relationship is most likely spurious and dependent
on an association between incipient cancer risk and attainment of
low levels of low-density lipoprotein. Unfortunately, they only
reported on the statin groups. It would have been helpful if they
excluded a similar association among the placebo groups and if
they had presented data excluding deaths within the first year after
onset of statin treatment, which may be confounders. In the
longest follow-up of any statin trial, 4S (Scandinavian Simvastatin
Survival Study) demonstrated that after 10 years there was a
nonsignificant trend toward less cancer among patients who
received simvastatin treatment during the trial period (5).
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Low Low-Density Lipoprotein
Cholesterol and Cancer Risk
The central finding in the report by Alsheikh-Ali et al. (1) was
Figure 9, which suggested a relationship between achieved low-
density lipoprotein (LDL) cholesterol and newly diagnosed can-
cers in 13 arms of statin trials. I suggest that the relationship is
confounded by age in various trials. The authors accounted for
sample size, but seemingly not for age, which is a bit surprising, as
age-adjustment is one of the most frequent procedures in epide-
miologic research. Are there some specific reasons for not doing
so? In any case, reasons are not stated.
Figure 1 Dependence of Yearly Cancer Incidence
on Age in Patients Treated With Statins
Cancer incidence was calculated from data provided in Alsheikh-Ali et al. (1).
AFCAPS  Air Force Texas Coronary Atherosclerosis Prevention Study;
ALLHAT  Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
Attack Trial; CARE  Cardiac Angiography in REnally impaired patients; HPS 
Medical Research Council/British Heart Foundation Heart Protection Study;
LIPID  Long-Term Intervention With Pravastatin in Ischemic Disease Trial;
PROSPER  Prospective Study of Pravastatin in the Elderly at Risk; WOS 
West of Scotland trial; 4S  Scandinavian Simvastatin Survival Study.
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